Exclusive: Moldova clears first gene editing study for HBV in humans

Lei Lei Wu

News Reporter

Precision Biosciences has received clearance from regulators in the Eastern European country of Moldova to begin a human trial of a gene editor for chronic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Moldova clears first gene editing study for HBV in humans

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­clu­sive: Moldo­va clears first gene edit­ing study for HBV in hu­mans

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: Moldova clears first gene editing study for HBV in humans